Business
Notice of Results & Update
Notice of Results & Update.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n Sareum Holdings PLC\n12 January 2007\n\n\nFor immediate release 12 January 2007\n\n\n\n SAREUM HOLDINGS PLC\n (\"Sareum\" or the \"Company\")\n\n\n Notice of Interim Results and R&D Update\n\n\nSareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery\nbusiness, will be announcing its interim results for the six months ended 31\nDecember 2006 on Tuesday 6 February 2007.\n\n\nAn analyst presentation will take place on the day at 10:00am at Buchanan\nCommunications, 45 Moorfields, London EC2Y 9AE.\n\n\nIn addition, on the same day, Sareum will be providing a research and\ndevelopment update for analysts at 10.30am also at the offices of Buchanan\nCommunications.\n\n\nThe R&D update will include the following presentations:\n\n\nWhat big pharma needs from biotech\n\nProfessor David Tapolczay, Vice President, \nTechnology Development, GlaxoSmithKline\n\n\nLevering biotech collaborations to attract big pharma licencing deals\nDr Stephen Mayhew, Business Manager, Cancer Research Technology\n\n\nSareum's in-house pipeline and licencing strategy\nDr John Reader, Founder and VP Chemistry, Sareum\n\n\nCopies of all the presentations will be available from 9.30am on 6 February 2007\nfrom www.sareum.co.uk.\n\n\n\nFor further information please contact:\n\nBuchanan Communications 020 7466 5000\nTim Anderson, Mary-Jane Johnson, Simon Potter\n\n\n\nAbout Sareum Holdings plc\n\nSareum Holdings plc is a structure-based drug discovery business headquartered\nin Cambridge, UK. The Company was formed in August 2003 to discover new drugs\nfor the treatment of cancer. Sareum's unique approach aims to halve the time it\ntakes to discover new drug candidates.\n\n\nA structure-based approach to drug discovery relies on knowledge of the\nthree-dimensional structure of the proteins that cause disease. Once the\nstructure is known, potential drugs are designed to 'lock-in' to the protein\nwith the aim of reversing or arresting a disease's progression. Knowledge of\nthe structure of the potential drugs and how they 'lock-in' to their target\nprotein assists greatly in the development of high-quality drug candidates.\nDetermining structure is a complex task and requires leading-edge equipment and\nexperienced staff. Sareum's approach to structure determination utilises its\nproprietary protein expression platform in order to pr...